GeneOne Life Science Completes 2.98 Billion Won Debt-to-Equity Conversion in Vietnamese Subsidiary Dong-Il Interlining for Financial Restructuring


  • GeneOne Life Science converted 2.98 billion won of debt into equity in its Vietnamese subsidiary Dong-Il Interlining to improve the subsidiary's financial structure, acquiring 100% ownership.
  • The transaction was executed without cash outflow, converting a portion of the receivable into equity, representing 7.29% of the parent's equity.
  • Dong-Il Interlining has negative equity and recurring losses; this conversion is expected to reduce its debt ratio, but profitability remains a concern.
  • [AI Summary]This defensive capital allocation avoids shareholder dilution and supports a distressed subsidiary, but the lack of immediate growth impact minimizes the positive effect on shareholder value.

KOSPI Filing Information


  • [Correction of Description] Decision on Acquisition of Stocks and Equity Securities of Other Corporations
  • Company: GeneOne Life Science (011000)
  • Submission: GeneOne Life Science, Inc.
  • Under KRX KOSPI Market Division

  • Shares: 90,882,907
  • Price: 918 KRW
  • Market Cap: 83.4 B KRW